RAPT Therapeutics, Inc.
https://www.rapt.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RAPT Therapeutics, Inc.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Finance Watch: ORIC Raises $120m In Another Pandemic Era Biopharma IPO
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.
Finance Watch: Biopharma Stocks See Big Post-IPO Jumps
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- FLX Bio, Inc.